Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer

Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

(2012) K. Cocks et al.   EUROPEAN JOURNAL OF CANCER

Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer

(2012) Daniel A. Monti et al.   PLoS One

Comment on “Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer,” i.e., all we are saying is, give C a chance

(2011) Joseph J. Cullen et al.   FREE RADICAL BIOLOGY AND MEDICINE

Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer

(2011) Michael Graham Espey et al.   FREE RADICAL BIOLOGY AND MEDICINE

Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects

(2009) Julien Verrax et al.   FREE RADICAL BIOLOGY AND MEDICINE

Losing and finding a way at C: New promise for pharmacologic ascorbate in cancer treatment

(2009) Mark Levine et al.   FREE RADICAL BIOLOGY AND MEDICINE

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy

(2008) L. J. Hoffer et al.   ANNALS OF ONCOLOGY

Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs

(2008) M. L. Heaney et al.   CANCER RESEARCH

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL